Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trial

Clinical Infectious Diseases

Volumn 54, Issue 7, 2012, Pages 1013-1025

  Havens, Peter L ^a   Stephensen, Charles B ^b   Hazra, Rohan ^c   Flynn, Patricia M ^d   Wilson, Craig M ^e   Rutledge, Brandy ^f   Bethel, James ^f   Pan, Cynthia G ^a   Woodhouse, Leslie R ^b   Van Loan, Marta D ^b   Liu, Nancy ^f   Lujan Zilbermann, Jorge ^g   Baker, Alyne ^h   Kapogiannis, Bill G ^c   Mulligan, Kathleen ⁱ  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b AGRICULTURAL RESEARCH SERVICE   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f WESTAT   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; PARATHYROID HORMONE; PHOSPHATE; PLACEBO; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENINE; ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLECALCIFEROL; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; PARATHYROID HORMONE; PHOSPHONIC ACIDS; PLACEBOS; VITAMINS; YOUNG ADULT;

EID: 84858137629     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir968     Document Type: Article

References (39)

1. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505.
2. Judd A, Boyd KL, Stohr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 2010; 24:525-34.
3. Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS 2005; 19:2031-3. (Pubitemid 41669029)
4. Kinai E, Hanabusa H, Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses 2009; 25:387-94.
5. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48:e108-16.
6. Buchacz K, Brooks JT, Tong T, et al. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med 2006; 7:451-6. (Pubitemid 44269812)
7. Essig M, Duval X, Kaied FA, et al. Is phosphatemia the best tool to monitor renal tenofovir toxicity? J Acquir Immune Defic Syndr 2007; 46:256-8. (Pubitemid 47482626)
8. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23:689-96.
9. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
10. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretoviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:e711-18. (Pubitemid 46089998)
11. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005; 116:e846-54. (Pubitemid 46056464)
12. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-601.
13. Stellbrink H-J, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofoviremtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-72.
14. Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008; 13:1077-82.
15. Rosenvinge MM, Gedela K, Copas AJ, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr 2010; 54:496-9.
16. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009; 10:482-7.
17. Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr 2006; 83:1135-41. (Pubitemid 44713115)
18. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-81.
19. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89:5387-91. (Pubitemid 39518413)
20. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press, 2011. Available at: http://books.nap.edu/openbook.php?record-id513050. Accessed 21 November 2011.
21. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-54. (Pubitemid 46768608)
22. Cummings SR, Block G, McHenry K, Baron RB. Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol 1987; 126:796-802. (Pubitemid 17161303)
23. Fux CA, Christen A, Zgraggen S, et al. Effect of tenofovir on renal glomerular and tubular function. AIDS 2007; 21:1483-5. (Pubitemid 46988011)
24. Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res 2002; 17(Suppl 2): N87-94. (Pubitemid 35222318)
25. Marks KH, Kilav R, Naveh-Many T, Silver J. Calcium, phosphate, vitamin D, and the parathyroid. Pediatr Nephrol 1996; 10:364-7. (Pubitemid 26171091)
26. Domrongkitchaiporn S, Disthabanchong S, Cheawchanthanakij R, et al. Oral phosphate supplementation corrects hypophosphatemia and normalizes plasma FGF23 and 25-hydroxyvitamin D3 levels in women with chronic metabolic acidosis. Exp Clin Endocrinol Diabetes 2010; 118:105-12.
27. Sims NA, Gooi JH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 2008; 19:444-51.
28. Suda T, Ueno Y, Fujii K, Shinki T. Vitamin D and bone. J Cell Biochem 2003; 88:259-66. (Pubitemid 36119896)
29. Childs KE, Fishman SL, Constable C, et al. Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses 2010; 26:855-9.
30. von Borstel Smith M, Crofoot K, Rodriguez-Proteau R, Filtz TM. Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells. Toxicol In Vitro 2007; 21:855-62. (Pubitemid 46603245)
31. Lee RH, Lyles KW, Coló n-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother 2010; 8:34-46.
32. Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009; 5:611-9.
33. Grigsby IF, Pham L, Mansky LM, et al. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 2010; 394:48-53.
34. Grigsby IF, Pham L, Gopalakrishnan R, et al. Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts. Biochem Biophys Res Commun 2010; 391:1324-9.
35. Grigsby IF, Pham L, Mansky LM, et al. Tenofovir-associated bone density loss. Ther Clin Risk Manag 2010; 6:41-7.
36. Nakahama K-I. Cellular communications in bone homeostasis and repair. Cell Mol Life Sci 2010; 67:4001-9.
37. Kiser JJ, Fletcher CV, Flynn PM, et al. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother 2008; 52:631-7. (Pubitemid 351170838)
38. Heaney RP, Armas LAG, Shary JR, Bell NH, Binkley N, Hollis BW. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr 2008; 87:1738-42. (Pubitemid 351872637)
39. Arpadi SM, McMahon D, Abrams EJ, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics 2009; 123:e121-6.